GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...

J&J's Imaavy (nipocalimab-aahu) has received US Food and Drug Administration (FDA) approval for treating generalised ...

The slowdown in IPOs following tariff-associated turbulence and FDA reorganisation will soon pass, say industry investors.

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Biopharmaceutical drug company venture financing witnessed a downturn in Q1 2025 —a 20.2% decline from the $8.1bn raised in ...